Global Biosimilar Insulin Glargine Market Research Report 2023
Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours. Insulin glargine is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above.
According to QYResearch’s new survey, global Biosimilar Insulin Glargine market is projected to reach US$ 2476 million in 2029, increasing from US$ 2046.4 million in 2022, with the CAGR of 2.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biosimilar Insulin Glargine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Biosimilar Insulin Glargine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
According to QYResearch’s new survey, global Biosimilar Insulin Glargine market is projected to reach US$ 2476 million in 2029, increasing from US$ 2046.4 million in 2022, with the CAGR of 2.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biosimilar Insulin Glargine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Biosimilar Insulin Glargine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Eli Lilly
- Gan&Lee
- Tonghua Dongbao
- United Laboratory
- Geropharm
- Biocon
- Wockhardt
- Pre-filled
- Cartridge
- Hospital
- Retail Pharmacy
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
1 BIOSIMILAR INSULIN GLARGINE MARKET OVERVIEW
1.1 Product Overview and Scope of Biosimilar Insulin Glargine
1.2 Biosimilar Insulin Glargine Segment by Type
1.2.1 Global Biosimilar Insulin Glargine Market Value Comparison by Type (2023-2029)
1.2.2 Pre-filled
1.2.3 Cartridge
1.3 Biosimilar Insulin Glargine Segment by Application
1.3.1 Global Biosimilar Insulin Glargine Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Global Biosimilar Insulin Glargine Market Size Estimates and Forecasts
1.4.1 Global Biosimilar Insulin Glargine Revenue 2018-2029
1.4.2 Global Biosimilar Insulin Glargine Sales 2018-2029
1.4.3 Global Biosimilar Insulin Glargine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 BIOSIMILAR INSULIN GLARGINE MARKET COMPETITION BY MANUFACTURERS
2.1 Global Biosimilar Insulin Glargine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Biosimilar Insulin Glargine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Biosimilar Insulin Glargine Average Price by Manufacturers (2018-2023)
2.4 Global Biosimilar Insulin Glargine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Biosimilar Insulin Glargine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilar Insulin Glargine, Product Type & Application
2.7 Biosimilar Insulin Glargine Market Competitive Situation and Trends
2.7.1 Biosimilar Insulin Glargine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biosimilar Insulin Glargine Players Market Share by Revenue
2.7.3 Global Biosimilar Insulin Glargine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 BIOSIMILAR INSULIN GLARGINE RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Biosimilar Insulin Glargine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Biosimilar Insulin Glargine Global Biosimilar Insulin Glargine Sales by Region: 2018-2029
3.2.1 Global Biosimilar Insulin Glargine Sales by Region: 2018-2023
3.2.2 Global Biosimilar Insulin Glargine Sales by Region: 2024-2029
3.3 Global Biosimilar Insulin Glargine Global Biosimilar Insulin Glargine Revenue by Region: 2018-2029
3.3.1 Global Biosimilar Insulin Glargine Revenue by Region: 2018-2023
3.3.2 Global Biosimilar Insulin Glargine Revenue by Region: 2024-2029
3.4 North America Biosimilar Insulin Glargine Market Facts & Figures by Country
3.4.1 North America Biosimilar Insulin Glargine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Biosimilar Insulin Glargine Sales by Country (2018-2029)
3.4.3 North America Biosimilar Insulin Glargine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biosimilar Insulin Glargine Market Facts & Figures by Country
3.5.1 Europe Biosimilar Insulin Glargine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Biosimilar Insulin Glargine Sales by Country (2018-2029)
3.5.3 Europe Biosimilar Insulin Glargine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilar Insulin Glargine Market Facts & Figures by Country
3.6.1 Asia Pacific Biosimilar Insulin Glargine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Biosimilar Insulin Glargine Sales by Country (2018-2029)
3.6.3 Asia Pacific Biosimilar Insulin Glargine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biosimilar Insulin Glargine Market Facts & Figures by Country
3.7.1 Latin America Biosimilar Insulin Glargine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Biosimilar Insulin Glargine Sales by Country (2018-2029)
3.7.3 Latin America Biosimilar Insulin Glargine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biosimilar Insulin Glargine Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilar Insulin Glargine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Biosimilar Insulin Glargine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Biosimilar Insulin Glargine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global Biosimilar Insulin Glargine Sales by Type (2018-2029)
4.1.1 Global Biosimilar Insulin Glargine Sales by Type (2018-2023)
4.1.2 Global Biosimilar Insulin Glargine Sales by Type (2024-2029)
4.1.3 Global Biosimilar Insulin Glargine Sales Market Share by Type (2018-2029)
4.2 Global Biosimilar Insulin Glargine Revenue by Type (2018-2029)
4.2.1 Global Biosimilar Insulin Glargine Revenue by Type (2018-2023)
4.2.2 Global Biosimilar Insulin Glargine Revenue by Type (2024-2029)
4.2.3 Global Biosimilar Insulin Glargine Revenue Market Share by Type (2018-2029)
4.3 Global Biosimilar Insulin Glargine Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global Biosimilar Insulin Glargine Sales by Application (2018-2029)
5.1.1 Global Biosimilar Insulin Glargine Sales by Application (2018-2023)
5.1.2 Global Biosimilar Insulin Glargine Sales by Application (2024-2029)
5.1.3 Global Biosimilar Insulin Glargine Sales Market Share by Application (2018-2029)
5.2 Global Biosimilar Insulin Glargine Revenue by Application (2018-2029)
5.2.1 Global Biosimilar Insulin Glargine Revenue by Application (2018-2023)
5.2.2 Global Biosimilar Insulin Glargine Revenue by Application (2024-2029)
5.2.3 Global Biosimilar Insulin Glargine Revenue Market Share by Application (2018-2029)
5.3 Global Biosimilar Insulin Glargine Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Eli Lilly Biosimilar Insulin Glargine Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Gan&Lee
6.2.1 Gan&Lee Corporation Information
6.2.2 Gan&Lee Description and Business Overview
6.2.3 Gan&Lee Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Gan&Lee Biosimilar Insulin Glargine Product Portfolio
6.2.5 Gan&Lee Recent Developments/Updates
6.3 Tonghua Dongbao
6.3.1 Tonghua Dongbao Corporation Information
6.3.2 Tonghua Dongbao Description and Business Overview
6.3.3 Tonghua Dongbao Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Tonghua Dongbao Biosimilar Insulin Glargine Product Portfolio
6.3.5 Tonghua Dongbao Recent Developments/Updates
6.4 United Laboratory
6.4.1 United Laboratory Corporation Information
6.4.2 United Laboratory Description and Business Overview
6.4.3 United Laboratory Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 United Laboratory Biosimilar Insulin Glargine Product Portfolio
6.4.5 United Laboratory Recent Developments/Updates
6.5 Geropharm
6.5.1 Geropharm Corporation Information
6.5.2 Geropharm Description and Business Overview
6.5.3 Geropharm Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Geropharm Biosimilar Insulin Glargine Product Portfolio
6.5.5 Geropharm Recent Developments/Updates
6.6 Biocon
6.6.1 Biocon Corporation Information
6.6.2 Biocon Description and Business Overview
6.6.3 Biocon Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Biocon Biosimilar Insulin Glargine Product Portfolio
6.6.5 Biocon Recent Developments/Updates
6.7 Wockhardt
6.6.1 Wockhardt Corporation Information
6.6.2 Wockhardt Description and Business Overview
6.6.3 Wockhardt Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Wockhardt Biosimilar Insulin Glargine Product Portfolio
6.7.5 Wockhardt Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 Biosimilar Insulin Glargine Industry Chain Analysis
7.2 Biosimilar Insulin Glargine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilar Insulin Glargine Production Mode & Process
7.4 Biosimilar Insulin Glargine Sales and Marketing
7.4.1 Biosimilar Insulin Glargine Sales Channels
7.4.2 Biosimilar Insulin Glargine Distributors
7.5 Biosimilar Insulin Glargine Customers
8 BIOSIMILAR INSULIN GLARGINE MARKET DYNAMICS
8.1 Biosimilar Insulin Glargine Industry Trends
8.2 Biosimilar Insulin Glargine Market Drivers
8.3 Biosimilar Insulin Glargine Market Challenges
8.4 Biosimilar Insulin Glargine Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Overview and Scope of Biosimilar Insulin Glargine
1.2 Biosimilar Insulin Glargine Segment by Type
1.2.1 Global Biosimilar Insulin Glargine Market Value Comparison by Type (2023-2029)
1.2.2 Pre-filled
1.2.3 Cartridge
1.3 Biosimilar Insulin Glargine Segment by Application
1.3.1 Global Biosimilar Insulin Glargine Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Global Biosimilar Insulin Glargine Market Size Estimates and Forecasts
1.4.1 Global Biosimilar Insulin Glargine Revenue 2018-2029
1.4.2 Global Biosimilar Insulin Glargine Sales 2018-2029
1.4.3 Global Biosimilar Insulin Glargine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 BIOSIMILAR INSULIN GLARGINE MARKET COMPETITION BY MANUFACTURERS
2.1 Global Biosimilar Insulin Glargine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Biosimilar Insulin Glargine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Biosimilar Insulin Glargine Average Price by Manufacturers (2018-2023)
2.4 Global Biosimilar Insulin Glargine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Biosimilar Insulin Glargine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilar Insulin Glargine, Product Type & Application
2.7 Biosimilar Insulin Glargine Market Competitive Situation and Trends
2.7.1 Biosimilar Insulin Glargine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biosimilar Insulin Glargine Players Market Share by Revenue
2.7.3 Global Biosimilar Insulin Glargine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 BIOSIMILAR INSULIN GLARGINE RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Biosimilar Insulin Glargine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Biosimilar Insulin Glargine Global Biosimilar Insulin Glargine Sales by Region: 2018-2029
3.2.1 Global Biosimilar Insulin Glargine Sales by Region: 2018-2023
3.2.2 Global Biosimilar Insulin Glargine Sales by Region: 2024-2029
3.3 Global Biosimilar Insulin Glargine Global Biosimilar Insulin Glargine Revenue by Region: 2018-2029
3.3.1 Global Biosimilar Insulin Glargine Revenue by Region: 2018-2023
3.3.2 Global Biosimilar Insulin Glargine Revenue by Region: 2024-2029
3.4 North America Biosimilar Insulin Glargine Market Facts & Figures by Country
3.4.1 North America Biosimilar Insulin Glargine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Biosimilar Insulin Glargine Sales by Country (2018-2029)
3.4.3 North America Biosimilar Insulin Glargine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biosimilar Insulin Glargine Market Facts & Figures by Country
3.5.1 Europe Biosimilar Insulin Glargine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Biosimilar Insulin Glargine Sales by Country (2018-2029)
3.5.3 Europe Biosimilar Insulin Glargine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilar Insulin Glargine Market Facts & Figures by Country
3.6.1 Asia Pacific Biosimilar Insulin Glargine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Biosimilar Insulin Glargine Sales by Country (2018-2029)
3.6.3 Asia Pacific Biosimilar Insulin Glargine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biosimilar Insulin Glargine Market Facts & Figures by Country
3.7.1 Latin America Biosimilar Insulin Glargine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Biosimilar Insulin Glargine Sales by Country (2018-2029)
3.7.3 Latin America Biosimilar Insulin Glargine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biosimilar Insulin Glargine Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilar Insulin Glargine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Biosimilar Insulin Glargine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Biosimilar Insulin Glargine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global Biosimilar Insulin Glargine Sales by Type (2018-2029)
4.1.1 Global Biosimilar Insulin Glargine Sales by Type (2018-2023)
4.1.2 Global Biosimilar Insulin Glargine Sales by Type (2024-2029)
4.1.3 Global Biosimilar Insulin Glargine Sales Market Share by Type (2018-2029)
4.2 Global Biosimilar Insulin Glargine Revenue by Type (2018-2029)
4.2.1 Global Biosimilar Insulin Glargine Revenue by Type (2018-2023)
4.2.2 Global Biosimilar Insulin Glargine Revenue by Type (2024-2029)
4.2.3 Global Biosimilar Insulin Glargine Revenue Market Share by Type (2018-2029)
4.3 Global Biosimilar Insulin Glargine Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global Biosimilar Insulin Glargine Sales by Application (2018-2029)
5.1.1 Global Biosimilar Insulin Glargine Sales by Application (2018-2023)
5.1.2 Global Biosimilar Insulin Glargine Sales by Application (2024-2029)
5.1.3 Global Biosimilar Insulin Glargine Sales Market Share by Application (2018-2029)
5.2 Global Biosimilar Insulin Glargine Revenue by Application (2018-2029)
5.2.1 Global Biosimilar Insulin Glargine Revenue by Application (2018-2023)
5.2.2 Global Biosimilar Insulin Glargine Revenue by Application (2024-2029)
5.2.3 Global Biosimilar Insulin Glargine Revenue Market Share by Application (2018-2029)
5.3 Global Biosimilar Insulin Glargine Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Eli Lilly Biosimilar Insulin Glargine Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Gan&Lee
6.2.1 Gan&Lee Corporation Information
6.2.2 Gan&Lee Description and Business Overview
6.2.3 Gan&Lee Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Gan&Lee Biosimilar Insulin Glargine Product Portfolio
6.2.5 Gan&Lee Recent Developments/Updates
6.3 Tonghua Dongbao
6.3.1 Tonghua Dongbao Corporation Information
6.3.2 Tonghua Dongbao Description and Business Overview
6.3.3 Tonghua Dongbao Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Tonghua Dongbao Biosimilar Insulin Glargine Product Portfolio
6.3.5 Tonghua Dongbao Recent Developments/Updates
6.4 United Laboratory
6.4.1 United Laboratory Corporation Information
6.4.2 United Laboratory Description and Business Overview
6.4.3 United Laboratory Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 United Laboratory Biosimilar Insulin Glargine Product Portfolio
6.4.5 United Laboratory Recent Developments/Updates
6.5 Geropharm
6.5.1 Geropharm Corporation Information
6.5.2 Geropharm Description and Business Overview
6.5.3 Geropharm Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Geropharm Biosimilar Insulin Glargine Product Portfolio
6.5.5 Geropharm Recent Developments/Updates
6.6 Biocon
6.6.1 Biocon Corporation Information
6.6.2 Biocon Description and Business Overview
6.6.3 Biocon Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Biocon Biosimilar Insulin Glargine Product Portfolio
6.6.5 Biocon Recent Developments/Updates
6.7 Wockhardt
6.6.1 Wockhardt Corporation Information
6.6.2 Wockhardt Description and Business Overview
6.6.3 Wockhardt Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Wockhardt Biosimilar Insulin Glargine Product Portfolio
6.7.5 Wockhardt Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 Biosimilar Insulin Glargine Industry Chain Analysis
7.2 Biosimilar Insulin Glargine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilar Insulin Glargine Production Mode & Process
7.4 Biosimilar Insulin Glargine Sales and Marketing
7.4.1 Biosimilar Insulin Glargine Sales Channels
7.4.2 Biosimilar Insulin Glargine Distributors
7.5 Biosimilar Insulin Glargine Customers
8 BIOSIMILAR INSULIN GLARGINE MARKET DYNAMICS
8.1 Biosimilar Insulin Glargine Industry Trends
8.2 Biosimilar Insulin Glargine Market Drivers
8.3 Biosimilar Insulin Glargine Market Challenges
8.4 Biosimilar Insulin Glargine Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
LIST OF TABLES
Table 1. Global Biosimilar Insulin Glargine Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Biosimilar Insulin Glargine Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Biosimilar Insulin Glargine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Biosimilar Insulin Glargine Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Biosimilar Insulin Glargine Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Biosimilar Insulin Glargine Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Biosimilar Insulin Glargine Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Biosimilar Insulin Glargine, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Biosimilar Insulin Glargine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Biosimilar Insulin Glargine, Product Type & Application
Table 12. Global Key Manufacturers of Biosimilar Insulin Glargine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biosimilar Insulin Glargine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Insulin Glargine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Biosimilar Insulin Glargine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Biosimilar Insulin Glargine Sales by Region (2018-2023) & (K Units)
Table 18. Global Biosimilar Insulin Glargine Sales Market Share by Region (2018-2023)
Table 19. Global Biosimilar Insulin Glargine Sales by Region (2024-2029) & (K Units)
Table 20. Global Biosimilar Insulin Glargine Sales Market Share by Region (2024-2029)
Table 21. Global Biosimilar Insulin Glargine Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Biosimilar Insulin Glargine Revenue Market Share by Region (2018-2023)
Table 23. Global Biosimilar Insulin Glargine Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Biosimilar Insulin Glargine Revenue Market Share by Region (2024-2029)
Table 25. North America Biosimilar Insulin Glargine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Biosimilar Insulin Glargine Sales by Country (2018-2023) & (K Units)
Table 27. North America Biosimilar Insulin Glargine Sales by Country (2024-2029) & (K Units)
Table 28. North America Biosimilar Insulin Glargine Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Biosimilar Insulin Glargine Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Biosimilar Insulin Glargine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Biosimilar Insulin Glargine Sales by Country (2018-2023) & (K Units)
Table 32. Europe Biosimilar Insulin Glargine Sales by Country (2024-2029) & (K Units)
Table 33. Europe Biosimilar Insulin Glargine Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Biosimilar Insulin Glargine Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Biosimilar Insulin Glargine Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Biosimilar Insulin Glargine Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Biosimilar Insulin Glargine Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Biosimilar Insulin Glargine Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Biosimilar Insulin Glargine Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Biosimilar Insulin Glargine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Biosimilar Insulin Glargine Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Biosimilar Insulin Glargine Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Biosimilar Insulin Glargine Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Biosimilar Insulin Glargine Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Biosimilar Insulin Glargine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Biosimilar Insulin Glargine Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Biosimilar Insulin Glargine Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Biosimilar Insulin Glargine Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Biosimilar Insulin Glargine Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Biosimilar Insulin Glargine Sales (K Units) by Type (2018-2023)
Table 51. Global Biosimilar Insulin Glargine Sales (K Units) by Type (2024-2029)
Table 52. Global Biosimilar Insulin Glargine Sales Market Share by Type (2018-2023)
Table 53. Global Biosimilar Insulin Glargine Sales Market Share by Type (2024-2029)
Table 54. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Biosimilar Insulin Glargine Revenue Market Share by Type (2018-2023)
Table 57. Global Biosimilar Insulin Glargine Revenue Market Share by Type (2024-2029)
Table 58. Global Biosimilar Insulin Glargine Price (US$/Unit) by Type (2018-2023)
Table 59. Global Biosimilar Insulin Glargine Price (US$/Unit) by Type (2024-2029)
Table 60. Global Biosimilar Insulin Glargine Sales (K Units) by Application (2018-2023)
Table 61. Global Biosimilar Insulin Glargine Sales (K Units) by Application (2024-2029)
Table 62. Global Biosimilar Insulin Glargine Sales Market Share by Application (2018-2023)
Table 63. Global Biosimilar Insulin Glargine Sales Market Share by Application (2024-2029)
Table 64. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Biosimilar Insulin Glargine Revenue Market Share by Application (2018-2023)
Table 67. Global Biosimilar Insulin Glargine Revenue Market Share by Application (2024-2029)
Table 68. Global Biosimilar Insulin Glargine Price (US$/Unit) by Application (2018-2023)
Table 69. Global Biosimilar Insulin Glargine Price (US$/Unit) by Application (2024-2029)
Table 70. Eli Lilly Corporation Information
Table 71. Eli Lilly Description and Business Overview
Table 72. Eli Lilly Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Eli Lilly Biosimilar Insulin Glargine Product
Table 74. Eli Lilly Recent Developments/Updates
Table 75. Gan&Lee Corporation Information
Table 76. Gan&Lee Description and Business Overview
Table 77. Gan&Lee Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Gan&Lee Biosimilar Insulin Glargine Product
Table 79. Gan&Lee Recent Developments/Updates
Table 80. Tonghua Dongbao Corporation Information
Table 81. Tonghua Dongbao Description and Business Overview
Table 82. Tonghua Dongbao Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Tonghua Dongbao Biosimilar Insulin Glargine Product
Table 84. Tonghua Dongbao Recent Developments/Updates
Table 85. United Laboratory Corporation Information
Table 86. United Laboratory Description and Business Overview
Table 87. United Laboratory Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. United Laboratory Biosimilar Insulin Glargine Product
Table 89. United Laboratory Recent Developments/Updates
Table 90. Geropharm Corporation Information
Table 91. Geropharm Description and Business Overview
Table 92. Geropharm Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Geropharm Biosimilar Insulin Glargine Product
Table 94. Geropharm Recent Developments/Updates
Table 95. Biocon Corporation Information
Table 96. Biocon Description and Business Overview
Table 97. Biocon Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Biocon Biosimilar Insulin Glargine Product
Table 99. Biocon Recent Developments/Updates
Table 100. Wockhardt Corporation Information
Table 101. Wockhardt Description and Business Overview
Table 102. Wockhardt Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Wockhardt Biosimilar Insulin Glargine Product
Table 104. Wockhardt Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Biosimilar Insulin Glargine Distributors List
Table 108. Biosimilar Insulin Glargine Customers List
Table 109. Biosimilar Insulin Glargine Market Trends
Table 110. Biosimilar Insulin Glargine Market Drivers
Table 111. Biosimilar Insulin Glargine Market Challenges
Table 112. Biosimilar Insulin Glargine Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
Table 1. Global Biosimilar Insulin Glargine Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Biosimilar Insulin Glargine Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Biosimilar Insulin Glargine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Biosimilar Insulin Glargine Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Biosimilar Insulin Glargine Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Biosimilar Insulin Glargine Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Biosimilar Insulin Glargine Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Biosimilar Insulin Glargine, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Biosimilar Insulin Glargine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Biosimilar Insulin Glargine, Product Type & Application
Table 12. Global Key Manufacturers of Biosimilar Insulin Glargine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biosimilar Insulin Glargine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Insulin Glargine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Biosimilar Insulin Glargine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Biosimilar Insulin Glargine Sales by Region (2018-2023) & (K Units)
Table 18. Global Biosimilar Insulin Glargine Sales Market Share by Region (2018-2023)
Table 19. Global Biosimilar Insulin Glargine Sales by Region (2024-2029) & (K Units)
Table 20. Global Biosimilar Insulin Glargine Sales Market Share by Region (2024-2029)
Table 21. Global Biosimilar Insulin Glargine Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Biosimilar Insulin Glargine Revenue Market Share by Region (2018-2023)
Table 23. Global Biosimilar Insulin Glargine Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Biosimilar Insulin Glargine Revenue Market Share by Region (2024-2029)
Table 25. North America Biosimilar Insulin Glargine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Biosimilar Insulin Glargine Sales by Country (2018-2023) & (K Units)
Table 27. North America Biosimilar Insulin Glargine Sales by Country (2024-2029) & (K Units)
Table 28. North America Biosimilar Insulin Glargine Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Biosimilar Insulin Glargine Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Biosimilar Insulin Glargine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Biosimilar Insulin Glargine Sales by Country (2018-2023) & (K Units)
Table 32. Europe Biosimilar Insulin Glargine Sales by Country (2024-2029) & (K Units)
Table 33. Europe Biosimilar Insulin Glargine Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Biosimilar Insulin Glargine Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Biosimilar Insulin Glargine Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Biosimilar Insulin Glargine Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Biosimilar Insulin Glargine Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Biosimilar Insulin Glargine Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Biosimilar Insulin Glargine Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Biosimilar Insulin Glargine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Biosimilar Insulin Glargine Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Biosimilar Insulin Glargine Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Biosimilar Insulin Glargine Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Biosimilar Insulin Glargine Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Biosimilar Insulin Glargine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Biosimilar Insulin Glargine Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Biosimilar Insulin Glargine Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Biosimilar Insulin Glargine Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Biosimilar Insulin Glargine Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Biosimilar Insulin Glargine Sales (K Units) by Type (2018-2023)
Table 51. Global Biosimilar Insulin Glargine Sales (K Units) by Type (2024-2029)
Table 52. Global Biosimilar Insulin Glargine Sales Market Share by Type (2018-2023)
Table 53. Global Biosimilar Insulin Glargine Sales Market Share by Type (2024-2029)
Table 54. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Biosimilar Insulin Glargine Revenue Market Share by Type (2018-2023)
Table 57. Global Biosimilar Insulin Glargine Revenue Market Share by Type (2024-2029)
Table 58. Global Biosimilar Insulin Glargine Price (US$/Unit) by Type (2018-2023)
Table 59. Global Biosimilar Insulin Glargine Price (US$/Unit) by Type (2024-2029)
Table 60. Global Biosimilar Insulin Glargine Sales (K Units) by Application (2018-2023)
Table 61. Global Biosimilar Insulin Glargine Sales (K Units) by Application (2024-2029)
Table 62. Global Biosimilar Insulin Glargine Sales Market Share by Application (2018-2023)
Table 63. Global Biosimilar Insulin Glargine Sales Market Share by Application (2024-2029)
Table 64. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Biosimilar Insulin Glargine Revenue Market Share by Application (2018-2023)
Table 67. Global Biosimilar Insulin Glargine Revenue Market Share by Application (2024-2029)
Table 68. Global Biosimilar Insulin Glargine Price (US$/Unit) by Application (2018-2023)
Table 69. Global Biosimilar Insulin Glargine Price (US$/Unit) by Application (2024-2029)
Table 70. Eli Lilly Corporation Information
Table 71. Eli Lilly Description and Business Overview
Table 72. Eli Lilly Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Eli Lilly Biosimilar Insulin Glargine Product
Table 74. Eli Lilly Recent Developments/Updates
Table 75. Gan&Lee Corporation Information
Table 76. Gan&Lee Description and Business Overview
Table 77. Gan&Lee Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Gan&Lee Biosimilar Insulin Glargine Product
Table 79. Gan&Lee Recent Developments/Updates
Table 80. Tonghua Dongbao Corporation Information
Table 81. Tonghua Dongbao Description and Business Overview
Table 82. Tonghua Dongbao Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Tonghua Dongbao Biosimilar Insulin Glargine Product
Table 84. Tonghua Dongbao Recent Developments/Updates
Table 85. United Laboratory Corporation Information
Table 86. United Laboratory Description and Business Overview
Table 87. United Laboratory Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. United Laboratory Biosimilar Insulin Glargine Product
Table 89. United Laboratory Recent Developments/Updates
Table 90. Geropharm Corporation Information
Table 91. Geropharm Description and Business Overview
Table 92. Geropharm Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Geropharm Biosimilar Insulin Glargine Product
Table 94. Geropharm Recent Developments/Updates
Table 95. Biocon Corporation Information
Table 96. Biocon Description and Business Overview
Table 97. Biocon Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Biocon Biosimilar Insulin Glargine Product
Table 99. Biocon Recent Developments/Updates
Table 100. Wockhardt Corporation Information
Table 101. Wockhardt Description and Business Overview
Table 102. Wockhardt Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Wockhardt Biosimilar Insulin Glargine Product
Table 104. Wockhardt Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Biosimilar Insulin Glargine Distributors List
Table 108. Biosimilar Insulin Glargine Customers List
Table 109. Biosimilar Insulin Glargine Market Trends
Table 110. Biosimilar Insulin Glargine Market Drivers
Table 111. Biosimilar Insulin Glargine Market Challenges
Table 112. Biosimilar Insulin Glargine Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Product Picture of Biosimilar Insulin Glargine
Figure 2. Global Biosimilar Insulin Glargine Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Biosimilar Insulin Glargine Market Share by Type in 2022 & 2029
Figure 4. Pre-filled Product Picture
Figure 5. Cartridge Product Picture
Figure 6. Global Biosimilar Insulin Glargine Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Biosimilar Insulin Glargine Market Share by Application in 2022 & 2029
Figure 8. Hospital
Figure 9. Retail Pharmacy
Figure 10. Others
Figure 11. Global Biosimilar Insulin Glargine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Biosimilar Insulin Glargine Market Size (2018-2029) & (US$ Million)
Figure 13. Global Biosimilar Insulin Glargine Sales (2018-2029) & (K Units)
Figure 14. Global Biosimilar Insulin Glargine Average Price (US$/Unit) & (2018-2029)
Figure 15. Biosimilar Insulin Glargine Report Years Considered
Figure 16. Biosimilar Insulin Glargine Sales Share by Manufacturers in 2022
Figure 17. Global Biosimilar Insulin Glargine Revenue Share by Manufacturers in 2022
Figure 18. The Global 5 and 10 Largest Biosimilar Insulin Glargine Players: Market Share by Revenue in 2022
Figure 19. Biosimilar Insulin Glargine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 20. Global Biosimilar Insulin Glargine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 21. North America Biosimilar Insulin Glargine Sales Market Share by Country (2018-2029)
Figure 22. North America Biosimilar Insulin Glargine Revenue Market Share by Country (2018-2029)
Figure 23. United States Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Canada Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Europe Biosimilar Insulin Glargine Sales Market Share by Country (2018-2029)
Figure 26. Europe Biosimilar Insulin Glargine Revenue Market Share by Country (2018-2029)
Figure 27. Germany Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. France Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. U.K. Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Italy Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Russia Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Asia Pacific Biosimilar Insulin Glargine Sales Market Share by Region (2018-2029)
Figure 33. Asia Pacific Biosimilar Insulin Glargine Revenue Market Share by Region (2018-2029)
Figure 34. China Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Japan Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. South Korea Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. India Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Australia Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. China Taiwan Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Indonesia Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Thailand Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Malaysia Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Latin America Biosimilar Insulin Glargine Sales Market Share by Country (2018-2029)
Figure 44. Latin America Biosimilar Insulin Glargine Revenue Market Share by Country (2018-2029)
Figure 45. Mexico Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Brazil Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Argentina Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Biosimilar Insulin Glargine Sales Market Share by Country (2018-2029)
Figure 49. Middle East & Africa Biosimilar Insulin Glargine Revenue Market Share by Country (2018-2029)
Figure 50. Turkey Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Saudi Arabia Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. UAE Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Global Sales Market Share of Biosimilar Insulin Glargine by Type (2018-2029)
Figure 54. Global Revenue Market Share of Biosimilar Insulin Glargine by Type (2018-2029)
Figure 55. Global Biosimilar Insulin Glargine Price (US$/Unit) by Type (2018-2029)
Figure 56. Global Sales Market Share of Biosimilar Insulin Glargine by Application (2018-2029)
Figure 57. Global Revenue Market Share of Biosimilar Insulin Glargine by Application (2018-2029)
Figure 58. Global Biosimilar Insulin Glargine Price (US$/Unit) by Application (2018-2029)
Figure 59. Biosimilar Insulin Glargine Value Chain
Figure 60. Biosimilar Insulin Glargine Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Figure 1. Product Picture of Biosimilar Insulin Glargine
Figure 2. Global Biosimilar Insulin Glargine Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Biosimilar Insulin Glargine Market Share by Type in 2022 & 2029
Figure 4. Pre-filled Product Picture
Figure 5. Cartridge Product Picture
Figure 6. Global Biosimilar Insulin Glargine Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Biosimilar Insulin Glargine Market Share by Application in 2022 & 2029
Figure 8. Hospital
Figure 9. Retail Pharmacy
Figure 10. Others
Figure 11. Global Biosimilar Insulin Glargine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Biosimilar Insulin Glargine Market Size (2018-2029) & (US$ Million)
Figure 13. Global Biosimilar Insulin Glargine Sales (2018-2029) & (K Units)
Figure 14. Global Biosimilar Insulin Glargine Average Price (US$/Unit) & (2018-2029)
Figure 15. Biosimilar Insulin Glargine Report Years Considered
Figure 16. Biosimilar Insulin Glargine Sales Share by Manufacturers in 2022
Figure 17. Global Biosimilar Insulin Glargine Revenue Share by Manufacturers in 2022
Figure 18. The Global 5 and 10 Largest Biosimilar Insulin Glargine Players: Market Share by Revenue in 2022
Figure 19. Biosimilar Insulin Glargine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 20. Global Biosimilar Insulin Glargine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 21. North America Biosimilar Insulin Glargine Sales Market Share by Country (2018-2029)
Figure 22. North America Biosimilar Insulin Glargine Revenue Market Share by Country (2018-2029)
Figure 23. United States Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Canada Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Europe Biosimilar Insulin Glargine Sales Market Share by Country (2018-2029)
Figure 26. Europe Biosimilar Insulin Glargine Revenue Market Share by Country (2018-2029)
Figure 27. Germany Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. France Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. U.K. Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Italy Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Russia Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Asia Pacific Biosimilar Insulin Glargine Sales Market Share by Region (2018-2029)
Figure 33. Asia Pacific Biosimilar Insulin Glargine Revenue Market Share by Region (2018-2029)
Figure 34. China Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Japan Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. South Korea Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. India Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Australia Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. China Taiwan Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Indonesia Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Thailand Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Malaysia Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Latin America Biosimilar Insulin Glargine Sales Market Share by Country (2018-2029)
Figure 44. Latin America Biosimilar Insulin Glargine Revenue Market Share by Country (2018-2029)
Figure 45. Mexico Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Brazil Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Argentina Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Biosimilar Insulin Glargine Sales Market Share by Country (2018-2029)
Figure 49. Middle East & Africa Biosimilar Insulin Glargine Revenue Market Share by Country (2018-2029)
Figure 50. Turkey Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Saudi Arabia Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. UAE Biosimilar Insulin Glargine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Global Sales Market Share of Biosimilar Insulin Glargine by Type (2018-2029)
Figure 54. Global Revenue Market Share of Biosimilar Insulin Glargine by Type (2018-2029)
Figure 55. Global Biosimilar Insulin Glargine Price (US$/Unit) by Type (2018-2029)
Figure 56. Global Sales Market Share of Biosimilar Insulin Glargine by Application (2018-2029)
Figure 57. Global Revenue Market Share of Biosimilar Insulin Glargine by Application (2018-2029)
Figure 58. Global Biosimilar Insulin Glargine Price (US$/Unit) by Application (2018-2029)
Figure 59. Biosimilar Insulin Glargine Value Chain
Figure 60. Biosimilar Insulin Glargine Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
